Fraunhofer-Gesellschaft

Publica

Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Ligand-modified human serum albumin nanoparticles for enhanced gene delivery

 
: Look, J.; Wilhelm, N.; Briesen, H. von; Noske, N.; Günther, C.; Langer, K.; Gorjup, E.

:

Molecular pharmaceutics 12 (2015), Nr.9, S.3202-3213
ISSN: 1543-8384
ISSN: 1543-8392
Bundesministerium für Bildung und Forschung BMBF
13N11539
Bundesministerium für Bildung und Forschung BMBF
13N11540
Bundesministerium für Bildung und Forschung BMBF
13N11541
Englisch
Zeitschriftenaufsatz
Fraunhofer IBMT ()

Abstract
The development of nonviral gene delivery systems is a great challenge to enable safe gene therapy. In this study, ligand-modified nanopartides based on human serum albumin (HSA) were developed and optimized for an efficient gene therapy. Different glutaraldehyde cross-linking degrees were investigated to optimize the HSA nanopartides for gene delivery. The peptide sequence arginine-glycine-aspartate (RGD) and the HIV-1 transactivator of transduction sequence (Tat) are well-known as promising targeting ligands. Plasmid DNA loaded HSA nanopartides were covalently modified on their surface with these different ligands. The transfection potential of the obtained plasmid DNA loaded RGD-and Tat-modified nanopartides was investigated in vitro, and optimal incubation conditions for these preparations were studied. It turned out that Tat-modified HSA nanopartides with the lowest cross-linking degree of 20% showed the highest transfection potential. Taken together, ligand-functionalized represent promising tools for efficient and safe gene therapy. HSA nanopartides

: http://publica.fraunhofer.de/dokumente/N-369543.html